With a unique governance model and a focus on cardiology, oncology, neuroscience, and immuno-inflammatory diseases, Servier aims to develop targeted and innovative therapies. The company also offers quality generic drugs to promote access to affordable healthcare. Headquartered in France, Servier operates in over 150 countries and generated €4.9 billion in revenue in 2022.